Fluvirin

PreclinicalBiologic

Novartis

Fluvirin is one of 23 biologic programs targeting Influenza. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfluenzaActive, not recruiting

InfluenzaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

Fluzone

GSK

Preclinical

37 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Crestor

AstraZeneca

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

COMIRNATY

Pfizer

Preclinical

1 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 10

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Influenza3 trials

Immune Responses Induced by Different Licensed Influenza Vaccines

Completed·UUniversity of Massachusetts, Worcester·N/A·NCT00902278·193 enrolled

Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth

Completed·IInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group··NCT01484522·149 enrolled

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04025580·98 enrolled

Immunogenicity1 trial

Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above

Completed· Novartis logo

Novartis·Phase 4·NCT01867021·2,902 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Fluvirin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluvirin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluvirin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: Novartis

Fluvirin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Influenza3 trials

Immunogenicity1 trial

References

Drug Info

Quick Facts

Related News